Studies CGRP-targeting migraine preventive medicines in real-world patients
Observes adults with migraine who take CGRP-targeting preventive drugs over 2 years.
Plain-language title generated from the registry record
Registry title: Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Key facts
- Where
- L’Aquila, Modena, Pavia, and Roma, ItalySee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who have been prescribed a CGRP-targeting preventive medicine and are followed over 2 years.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Migraine diagnosed according to ICHD-III.
- Earlier treatment
- Must have been prescribed erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant, following the prescriber's criteria and local reimbursement rules.
Main reasons for not taking part
- Headache other than migraine
- Active severe psychiatric condition that may affect the ability to consent
- Cognitive impairment that may affect the ability to consent
Read by machine on 12 November 2026.
Where in Italy
- University of L'AquilaL’Aquila, ItalyContact: Simona SaccoTaking people
- University of Modena and Reggio EmiliaModena, ItalyContact: Luigi IannoneTaking people
- National Neurological Institute C. Mondino FoundationPavia, ItalyContact: Cristina TassorelliTaking people
- IRCCS San RaffaeleRoma, ItalyContact: Piero BarbantiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT07159750
- Record updated
- 8 September 2025
- Original description
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.Read full original descriptionShow less
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Inclusion: Migraine diagnosis according to ICHD-III; Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations; Signature of informed consent.
Exclusion: Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study; Presence of headache different from migraine.